GpCRC Pediatric Gastroparesis Registry 2
Key facts
- Where
- Boston, Columbus, El Paso, Houston, and Milwaukee, United StatesSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 25 years old?
Source: NCT05981300, who can take part
Where in United States
- Boston Children's HospitalBoston, United StatesContact: Samuel Nurko, MDTaking people
- Massachusetts General HospitalBoston, United StatesContact: Nir Bar, MDTaking people
- Nationwide Children's HospitalColumbus, United StatesContact: Amina Usman, MDTaking people
- Texas Tech University Health Science CenterEl Paso, United StatesContact: Denease Francis, MDTaking people
- Baylor College of Medicine/ Texas Children's HospitalHouston, United StatesContact: Geoffrey A Preidis, MD, PhDTaking people
- Medical College of WisconsinMilwaukee, United StatesContact: Katja Karrento, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Johns Hopkins Bloomberg School of Public Health
- Trial code
- NCT05981300
- Record updated
- 3 April 2026
- Original description
The objective of the Pediatric Gastroparesis Registry 2 is to create a national prospective registry of children, adolescents, and young adults with gastroparesis and gastroparesis-like syndrome (symptoms of gastroparesis but normal gastric emptying).Read full original descriptionShow less
GpCRC Pediatric Gastroparesis Registry 2: Characterization and Clinical Course of Symptoms and Gastric Emptying in Pediatric, Adolescent, and Young Adult Participants With Symptoms of Gastroparesis
The objective of the Pediatric Gastroparesis Registry 2 is to create a national prospective registry of children, adolescents, and young adults with gastroparesis and gastroparesis-like syndrome (symptoms of gastroparesis but normal gastric emptying).
Inclusion: Provision of signed and dated informed consent form and assent, as age appropriate; Stated willingness to comply with all study procedures and availability for the duration of the study; 8 to 25 years of age at the time of enrollment; Symptoms of Gp of at least 12 weeks duration: constellation of some combination of:; nausea, vomiting, early satiety, postprandial fullness; symptoms sometimes may be accompanied by upper abdominal pain; Have undergone a gastric emptying scintigraphic study of solids using 4-hour Egg Beaters protocol (or equivalent generic liquid egg white meal) within the last 12 months who fall into one of the two categories:; Delayed gastric emptying-defined as an abnormal 2-hour (>60% retention) and/or 4- hour (>10% retention) result based on a 4-hour scintigraphic gastric emptying study; Gastric emptying that is not delayed but who have symptoms of Gp (designated in this study as GLS) or have previously participated in the Pediatric Gastroparesis Registry (PGpR) study; An etiology of either diabetic or idiopathic Gp or GLS.
Exclusion: Use of medications that can affect motility during the gastric emptying study; Inability to comply with or complete the scintigraphic gastric emptying test (including allergy to eggs); Autism spectrum disorder, significant developmental delay, psychosis (because of inability to complete questionnaires); Presence of conditions associated with GI mucosal disease (e.g., inflammatory bowel disease, known eosinophilic gastroenteritis or eosinophilic esophagitis, gastric ulcer, peptic ulcer, celiac disease); Presence of any other condition that could case delayed gastric emptying; Primary neurological conditions that can cause nausea and vomiting such as increased intracranial pressure, space occupying or inflammatory/infectious legions; Acute liver failure; Advanced liver disease (features of portal hypertension); Clinically significant congenital heart disease (i.e., vaginal injury during cardiac repair); History of esophageal, gastric or bowel surgery; Metabolic disease including mitochondrial disease and inborn errors of metabolism; Chronic lung disease (including cystic fibrosis); A serious chronic medical condition (e.g., inflammatory bowel disease); Any other condition, which in the option of the investigator, could explain the symptoms or could interfere with study requirements; Acute or chronic renal failure (abnormal creatinine for age) and /or on hemodialysis or peritoneal dialysis; Pregnancy; Use of narcotic analgesics greater than three days per week; Gastrointestinal construction confirmed by upper endoscopy (EGD), upper gastrointestinal series (UGI), or abdominal CT.